Ciclesonide
Brand names: Alvesco
Ciclesonide is an inhaled corticosteroid prodrug used for the regular preventive treatment of asthma.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is activated by esterases in the airways to its active metabolite, which binds glucocorticoid receptors to reduce airway inflammation while limiting systemic and oropharyngeal exposure.
Prescribing in practice
- It is a preventer for regular use and does not relieve acute bronchospasm, so a reliever inhaler remains necessary.
- As with all inhaled corticosteroids, sustained high exposure can produce systemic corticosteroid effects.
- Correct inhaler technique should be confirmed to ensure effective lung deposition.
Monitoring
Monitor asthma control, inhaler technique and, in children, growth during continued therapy.
Counselling the patient
- Use every day as a preventer, even when symptom-free.
- Keep a reliever inhaler for sudden breathlessness.
- Local airway activation means mouth thrush is less common, but rinsing remains good practice.
Evidence & guidelines
Inhaled corticosteroids including ciclesonide are supported as maintenance asthma therapy in national asthma guidance.
Reference: SmPC Alvesco; BTS/SIGN Asthma 158 (2019); GINA 2024; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024